Keith W. Pfeil - 10 Jan 2025 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role
COO, CFO
Signature
/s/ Kelly G. Huller, Attorney-in-Fact
Issuer symbol
GMED
Transactions as of
10 Jan 2025
Net transactions value
-$517,210
Form type
4
Filing time
14 Jan 2025, 16:12:57 UTC
Previous filing
30 Jan 2024
Next filing
28 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Options Exercise $289,608 +5,833 $49.65 5,833 10 Jan 2025 Direct
transaction GMED Class A Common Stock Options Exercise $443,952 +8,334 +143% $53.27 14,167 10 Jan 2025 Direct
transaction GMED Class A Common Stock Sale $1,102,213 -12,501 -88% $88.17 1,666 10 Jan 2025 Direct F1, F2
transaction GMED Class A Common Stock Sale $148,557 -1,666 -100% $89.17 0 10 Jan 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -5,833 -100% $0.000000 0 10 Jan 2025 Class A Common Stock 5,833 $49.65 Direct F4
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -8,334 -91% $0.000000 833 10 Jan 2025 Class A Common Stock 8,334 $53.27 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan dated December 15, 2023 executed by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.60 to $88.55, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.69 to $89.63, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 These options were granted on September 3, 2019 and are fully vested.
F5 These options were granted on January 22, 2020 and are fully vested.